R1 Therapeutics Raises $77.5M Series A to Advance Kidney Disease Drug

Why It Matters

The capital infusion accelerates R1’s path to market, potentially delivering a more effective, patient‑friendly therapy for CKD—a condition with limited treatment options. Success could reshape the phosphate‑binder market and attract further investment into renal therapeutics.

Key Takeaways

• R1 secured $77.5M Series A for kidney disease drug
• AP306 blocks active phosphate transport, novel mechanism
• Phase 2b global trial slated later this year
• Abingworth, F‑Prime, DaVita lead investment round
• AP306 outperformed Renvela in Chinese Phase 2a

Pulse Analysis

The chronic kidney disease (CKD) market remains one of the most underserved segments in pharma, with hyperphosphatemia driving morbidity and hospitalizations. Existing phosphate binders such as sevelamer and Renvela require multiple daily pills and achieve modest target‑achievement rates. R1 Therapeutics' $77.5 million Series A, led by Abingworth, F‑Prime and DaVita Venture Group, signals strong investor confidence in a differentiated approach. By targeting the active transport of phosphate, the company hopes to reduce pill burden while improving biochemical control, a combination that could reshape standard of care for CKD patients worldwide.

AP306, the lead candidate acquired from Chugai and sublicensed by Alebund Pharmaceuticals, is the first pan‑phosphate transporter inhibitor that blocks the active uptake pathway. In a Phase 2a study conducted in China, the drug lowered serum phosphate more effectively than Renvela, with roughly 20 % more patients reaching KDIGO‑recommended levels. The trial’s favorable safety profile and reduced tablet count underpin R1’s claim of a lower pill burden. A global Phase 2b trial, co‑managed with Alebund, is slated to start later this year, expanding enrollment beyond Greater China.

The sizable Series A round places R1 among a wave of biotech firms attracting late‑stage capital for niche renal therapies. Investors such as DaVita see strategic alignment with dialysis services, while venture firms anticipate a multi‑billion‑dollar market for next‑generation phosphate control. If AP306 confirms its Phase 2b advantage, it could command premium pricing and fast‑track regulatory pathways, given the high unmet need. Moreover, the partnership model with Alebund illustrates a growing trend of cross‑border collaborations that de‑risk development while preserving regional rights. Success would not only validate R1’s science but also reinforce confidence in specialty kidney‑focused investments.

Deal Summary

R1 Therapeutics announced an oversubscribed $77.5 million Series A round to advance its first‑in‑class hyperphosphatemia treatment for chronic kidney disease. The round was co‑led by Abingworth, F‑Prime and DaVita Venture Group. The funding will support global development, including a Phase 2b study of AP306.